文献速递膀胱癌与上尿路尿路上皮癌

淋巴血管侵犯对手术治疗上尿路尿路上皮癌生存的影响:一项全国性分析

Impact of lymphovascular invasion on survival in surgically treated upper tract urothelial carcinoma: a nationwide analysis.
PubMed 文献 · BJU Int · 2024-01-08

基于美国国家癌症数据库2010至2016年5940例接受根治性肾输尿管切除术的临床M0上尿路尿路上皮癌患者,评估淋巴血管侵犯对总生存的预测价值。淋巴血管侵犯与较差的总生存相关(风险比1.79,95%置信区间1.60-1.99;P<0.001)。

要点

  • 淋巴血管侵犯患者5年总生存率为28%,无淋巴血管侵犯者为66%(P<0.001)。
  • 多变量分析显示淋巴血管侵犯与较差总生存相关(风险比1.79,95%置信区间1.60-1.99;P<0.001)。
  • 淋巴血管侵犯可用于预后咨询,并可能作为未来试验风险分层的工具。

核心结论

  • 淋巴血管侵犯与根治性肾输尿管切除术后上尿路尿路上皮癌患者较差的总生存相关。
  • 该变量可用于预后咨询,并可能作为未来试验风险分层的工具。

研究设计与样本

  • 回顾性队列研究,纳入美国国家癌症数据库2010至2016年5940例接受根治性肾输尿管切除术的临床M0上尿路尿路上皮癌患者。
  • 主要变量为淋巴血管侵犯状态及其与病理淋巴结状态的交互作用。

主要发现

  • 诊断时中位年龄为71岁(四分位距63-78岁),多数患者为病理T1期(48.6%)。
  • 淋巴结状态为pN0、pN1和pNx者分别占45.8%、6.3%和47.9%。
  • 22.1%的患者存在淋巴血管侵犯。
  • 中位随访时间为32.6个月(四分位距16.0-53.3个月)。
  • 术后5年总生存率:淋巴血管侵犯患者为28%,无淋巴血管侵犯者为66%(P<0.001);按淋巴结状态分层,pN0患者为32% vs 68%(P<0.001),pN1患者为23% vs 30%(P=0.8),pNx患者为28% vs 65%(P<0.001)。

关键数值与推荐

  • 淋巴血管侵犯患者5年总生存率为28%,无淋巴血管侵犯者为66%(P<0.001)。
  • pN0患者中,淋巴血管侵犯者5年总生存率为32%,无淋巴血管侵犯者为68%(P<0.001)。
  • pN1患者中,淋巴血管侵犯者5年总生存率为23%,无淋巴血管侵犯者为30%(P=0.8)。
  • pNx患者中,淋巴血管侵犯者5年总生存率为28%,无淋巴血管侵犯者为65%(P<0.001)。
  • 多变量分析中,淋巴血管侵犯与较差总生存相关(风险比1.79,95%置信区间1.60-1.99;P<0.001)。

临床怎么用

  • 作者认为,淋巴血管侵犯可用于向患者咨询预后,并可能作为未来试验风险分层的工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the prognostic ability of lymphovascular invasion (LVI) in upper tract urothelial carcinoma (UTUC) as a predictor of overall survival (OS) using a large North American cohort. PATIENTS AND METHODS: Our cohort included 5940 patients with clinical M0 UTUC who underwent a radical nephroureterectomy (RNU), between 2010 and 2016, within the National Cancer Database. The main variable of interest was LVI status, and its interaction with pathological nodal (pN) status. Kaplan-Meier curves were used to depict the OS also stratifying patients on LVI status. Cox regression analysis tested the impact of LVI status on OS after accounting for the available covariates. RESULTS: The median (interquartile range [IQR]) age at diagnosis was 71 (63-78) years and most patients had pathological T1 stage disease (48.6%). Nodal status was pN0, pN1 and pNx in 45.8%, 6.3% and 47.9%, respectively. Overall, 22.1% had LVI. The median (IQR) follow-up time was 32.6 (16.0-53.3) months. At the 5-year postoperative follow-up, the estimated OS rate was 28% in patients with LVI vs 66% in those without LVI (P < 0.001). When patients were stratified based on nodal status those rates were 32% vs 68% in pN0 patients (P < 0.001), 23% vs 30% in pN1 patients (P = 0.8), and 28% vs 65% in pNx patients (P < 0.001). On multivariable analysis, the presence of LVI was associated with less favourable OS (hazard ratio 1.79, 95% confidence interval 1.60-1.99; P < 0.001). CONCLUSION: Our study assessed the impact of LVI on OS in patients with UTUC in a large North American nationwide cohort. Our series, as the largest to date, indicate that LVI is associated with less favourable survival outcomes in patients with UTUC after RNU, and this variable could be used in counselling patients about their prognosis and might be a useful tool for future trials to risk-stratify patients.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Cirulli GO, Corsi N, Rakic I, et al. Impact of lymphovascular invasion on survival in surgically treated upper tract urothelial carcinoma: a nationwide analysis. BJU Int. 2024. PMID: 38097533. doi:10.1111/bju.16258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。